Peritoneal Cancer Market

Market Overview:

The 7 major peritoneal cancer markets are expected to exhibit a CAGR of 18.2% during 2024-2034.

The peritoneal cancer market has been comprehensively analyzed in IMARC's new report titled "Peritoneal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Peritoneal cancer, also known as primary peritoneal carcinoma, is a type of cancer that originates in the peritoneum, a thin tissue lining the abdominal cavity. It can present itself with a variety of symptoms, although they can be nonspecific and overlap with other conditions. Some of the common indications associated with the ailment include abdominal pain or discomfort, bloating, changes in bowel habits, unexplained weight loss, fatigue, accumulation of fluid in the abdomen (ascites), loss of appetite, etc. These symptoms may be persistent and progressively worsen over time. The diagnosis of peritoneal cancer typically involves a combination of imaging tests, laboratory analysis, and pathological evaluation. Initially, a healthcare professional may conduct a thorough medical history and physical examination to assess symptoms and identify potential risk factors. Various imaging procedures, such as ultrasound, computed tomography (CT) scan, magnetic resonance imaging (MRI), etc., are commonly used to visualize the abdominal region and locate any abnormalities in the peritoneum. Additionally, laboratory tests are also performed to evaluate tumor markers or specific biomarkers associated with the ailment.

The increasing cases of genetic mutations and alterations in the DNA of peritoneal cells, which lead to uncontrolled cell growth and the development of cancerous tumors, are primarily driving the peritoneal cancer market. In addition to this, the emerging popularity of intraperitoneal chemotherapy, since it allows for high drug concentrations within the peritoneal cavity, thereby targeting cancer cells more effectively, is acting as another significant growth-inducing factor. Moreover, the inflating demand for hyperthermia-based therapies, which involve heating the tumor tissue to enhance the effectiveness of other treatment modalities, is further creating a positive outlook for the market. Additionally, numerous key players are making extensive investments in R&D activities to introduce antibody-drug conjugates (ADCs) that selectively deliver cytotoxic drugs to peritoneal cancer cells while minimizing toxicity to healthy tissues. This, in turn, is also bolstering the market growth. Furthermore, the emerging popularity of nanoparticle-based drug delivery systems on account of their several associated benefits, including enhanced drug delivery to tumor cells, reduced systemic toxicity, sustained release of chemotherapeutic agents, etc., is expected to drive the peritoneal cancer market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the peritoneal cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for peritoneal cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the peritoneal cancer market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the peritoneal cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the peritoneal cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current peritoneal cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the peritoneal cancer market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the peritoneal cancer market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the peritoneal cancer market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of peritoneal cancer across the seven major markets?
• What is the number of prevalent cases (2018-2034) of peritoneal cancer by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of peritoneal cancer by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with peritoneal cancer across the seven major markets?
• What is the size of the peritoneal cancer patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of peritoneal cancer?
• What will be the growth rate of patients across the seven major markets?
   

Peritoneal Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for peritoneal cancer drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the peritoneal cancer market?
• What are the key regulatory events related to the peritoneal cancer market?
• What is the structure of clinical trial landscape by status related to the peritoneal cancer market?
• What is the structure of clinical trial landscape by phase related to the peritoneal cancer market?
• What is the structure of clinical trial landscape by route of administration related to the peritoneal cancer market?